Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care.

"Declaration of Competing Interest Dr. Roy has served as a consultant/advisor for Alexion Pharmaceuticals. He does not have any conflicts of interest related to this article. Dr. Nowak reports no conflicts directly related to this publication. Dr. Nowak received research support from Alexion Pharmaceuticals, argenx, Genentech, Grifols, Immunovant, Momenta, the Myasthenia Gravis Foundation of America, the National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Institute of Allergy and Infectious Diseases), and Ra Pharma; and consultancy fees from Alexion Pharmaceuticals, argenx, CSL Behring, Grifols, Immunovant, Momenta, Ra Pharma, Roivant, and Viela Bio. Dr. Rutkove is a founder of the Myolex, Inc. He also reports equity in, and serves as a consultant and scientific advisor to, Myolex Inc.; he is also a member of the company's Board of Directors. Dr. Rutkove has also received consulting income from Biogen and Roche Pharmaceuticals. Dr. Llyod is in the scientific advisory board of Acceleron. He reports no conflicts directly related to this publication. Dr. Patwa has served as a speaker/advisor for Baxter and CSL. He reports no conflicts directly related to this publication. Dr. Roda reports no conflicts of interests. Dr. Khokhar reports no conflicts of interests."

"Funding None."